S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
The Strategic Gold Play You Haven't Heard About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
All the trading advice you’ve ever received boils down to this (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
The Strategic Gold Play You Haven't Heard About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
All the trading advice you’ve ever received boils down to this (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
The Strategic Gold Play You Haven't Heard About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
All the trading advice you’ve ever received boils down to this (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
Marvell Technology at a critical pivot: 30% upside is possible
What is dividend harvesting?
The Strategic Gold Play You Haven't Heard About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
All the trading advice you’ve ever received boils down to this (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Organon & Co. Stock Price, News & Analysis (NYSE:OGN)

$11.09
-0.74 (-6.26%)
(As of 12/5/2023 ET)
Compare
Today's Range
$11.07
$11.81
50-Day Range
$10.95
$17.37
52-Week Range
$10.90
$32.43
Volume
4.58 million shs
Average Volume
2.85 million shs
Market Capitalization
$2.83 billion
P/E Ratio
4.84
Dividend Yield
10.10%
Price Target
$23.33

Organon & Co. MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
110.4% Upside
$23.33 Price Target
Short Interest
Bearish
5.73% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.38
Upright™ Environmental Score
News Sentiment
-0.66mentions of Organon & Co. in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
2.72%
From $4.05 to $4.16 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.79 out of 5 stars

Medical Sector

57th out of 948 stocks

Pharmaceutical Preparations Industry

12th out of 421 stocks


OGN stock logo

About Organon & Co. Stock (NYSE:OGN)

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

OGN Stock Price History

OGN Stock News Headlines

Organon: It's Darkest Before The Dawn
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Analyst Expectations for Organon's Future
Organon & Co Ordinary Shares
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Analyst Ratings for Organon
Organon & Co. (NYSE:OGN) Q3 2023 Earnings Call Transcript
Organon & Co (OGN) Declined in Q3
See More Headlines
Receive OGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/14 Dividend
8/17/2023
Dividend Payable
9/14/2023
Last Earnings
11/02/2023
Ex-Dividend for 12/14 Dividend
11/10/2023
Today
12/06/2023
Dividend Payable
12/14/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/15/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
10,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.33
High Stock Price Target
$33.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+110.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$917 million
Pretax Margin
11.06%

Debt

Sales & Book Value

Annual Sales
$6.15 billion
Cash Flow
$5.66 per share
Book Value
($3.51) per share

Miscellaneous

Free Float
252,615,000
Market Cap
$2.83 billion
Optionable
Not Optionable
Beta
0.65
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Kevin Ali (Age 63)
    CEO & Director
    Comp: $3.96M
  • Mr. Matthew M. Walsh (Age 56)
    Executive VP & CFO
    Comp: $1.84M
  • Ms. Susanne Gabriele Fiedler (Age 55)
    Executive VP & Chief Commercial Officer
    Comp: $1.44M
  • Dr. Sandra Milligan J.D. (Age 59)
    M.D., Executive VP and Head of Research & Development
    Comp: $1.6M
  • Mr. Joseph T. Morrissey Jr. (Age 58)
    Executive VP and Head of Manufacturing & Supply
    Comp: $1.54M
  • Ms. Rachel A. Stahler (Age 47)
    Executive VP & Chief Information Officer
  • Ms. Jennifer Halchak
    Vice President of Investor Relations
  • Mr. Kirke Weaver (Age 50)
    Executive VP, General Counsel & Corporate Secretary
  • Mr. Aaron Falcione (Age 52)
    Executive VP & Chief Human Resources Officer
  • Mr. Vittorio Nisita (Age 55)
    Executive VP & Head of Global Business Services














OGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Organon & Co. stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OGN shares.
View OGN analyst ratings
or view top-rated stocks.

What is Organon & Co.'s stock price target for 2024?

5 Wall Street research analysts have issued twelve-month price targets for Organon & Co.'s stock. Their OGN share price targets range from $16.00 to $33.00. On average, they predict the company's share price to reach $23.33 in the next year. This suggests a possible upside of 110.4% from the stock's current price.
View analysts price targets for OGN
or view top-rated stocks among Wall Street analysts.

How have OGN shares performed in 2023?

Organon & Co.'s stock was trading at $27.93 at the beginning of 2023. Since then, OGN shares have decreased by 60.3% and is now trading at $11.09.
View the best growth stocks for 2023 here
.

Are investors shorting Organon & Co.?

Organon & Co. saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 14,620,000 shares, an increase of 36.3% from the October 31st total of 10,730,000 shares. Based on an average daily volume of 4,550,000 shares, the days-to-cover ratio is presently 3.2 days. Currently, 5.7% of the company's stock are short sold.
View Organon & Co.'s Short Interest
.

When is Organon & Co.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our OGN earnings forecast
.

How were Organon & Co.'s earnings last quarter?

Organon & Co. (NYSE:OGN) announced its earnings results on Thursday, November, 2nd. The company reported $0.78 EPS for the quarter, missing analysts' consensus estimates of $1.04 by $0.26. The firm had revenue of $1.52 billion for the quarter, compared to analysts' expectations of $1.59 billion. Organon & Co. had a net margin of 9.51% and a negative trailing twelve-month return on equity of 147.13%.

How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?

Organon & Co. declared a quarterly dividend on Thursday, November 2nd. Stockholders of record on Monday, November 13th will be given a dividend of $0.28 per share on Thursday, December 14th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 10.10%. The ex-dividend date is Friday, November 10th.
Read our dividend analysis for OGN
.

Is Organon & Co. a good dividend stock?

Organon & Co. (NYSE:OGN) pays an annual dividend of $1.12 per share and currently has a dividend yield of 9.74%. OGN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 48.91%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, OGN will have a dividend payout ratio of 26.92% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for OGN.

Who are Organon & Co.'s major shareholders?

Organon & Co.'s stock is owned by a variety of retail and institutional investors. Top institutional investors include Mawer Investment Management Ltd. (5.03%), Invesco Ltd. (4.01%), Massachusetts Financial Services Co. MA (3.63%), Lord Abbett & CO. LLC (1.97%), Sound Shore Management Inc CT (1.35%) and Morgan Stanley (1.19%).
View institutional ownership trends
.

How do I buy shares of Organon & Co.?

Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:OGN) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -